Analysis for HCA Healthcare
Analysis summary
HCA Healthcare (HCA) currently has a total score of 80 points, placing it in the very strong range. The score is made up of Performance (89), Stability (64) and Trend (80). All three sub-scores are currently above average.
Performance scores 89 points (very strong). Key strength: 1Y return at 66.8 %. Even the weakest return is still strong in absolute terms: 3Y return at 109.5 %.
Stability scores 64 points (strong). Key strength: return/volatility ratio at 2.42. Main drag: max drawdown (10Y) at -54.9 %. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.
Trend scores 80 points (very strong). Key strength: Price is about 26.3 % above SMA200. Even the weakest metric remains solid in absolute terms: trend strength at 0.71. That often means the move is strong, but not perfectly steady.
Overall, the very strong total score is driven mainly by Performance and Trend; Stability is the biggest lever for improvement. On a metric level, return/volatility ratio stands out, while max drawdown (10Y) is the main weak spot.
(Historical evaluation, not investment advice.)
Metrics
Performance
Stability
FAQ
- What investor type does HCA Healthcare fit best in FoxScore?
- HCA Healthcare fits a more opportunity-seeking investor type in FoxScore: performance is the strongest sub-score. That suggests above-average historical returns — but check stability to ensure the performance wasn’t “paid for” with high volatility or deep drawdowns.
- How meaningful is the available history for HCA Healthcare?
- HCA Healthcare currently has about 14.9 years of price history since it started trading. That’s a solid base to interpret returns, drawdowns and trend behavior since launch — earlier market crises happened before the asset existed and are therefore not part of its history.
- What is FoxScore good for — and what is it not for?
- FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.